 | | Vol. 8.42 – 4 November, 2020 |
| |
|
|
| Investigators condensed over 120,000 immune features into a single axis to capture how different immune cell classes coordinated in response to SARS-CoV-2.
[Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| The authors report antibody and antibody-avidity assays, relying on near-infrared-fluorescence amplification by nanostructured plasmonic gold substrates, for the simultaneous detection of antibodies to the S1 subunit of the spike protein and to the receptor binding domain of SARS-CoV-2 in human serum and saliva.
[Nature Biomedical Engineering] |
|
|
|
| Investigators showed that among all viral proteins, Nsp1 has the largest impact on host viability in the cells of human lung origin.
[Molecular Cell] |
|
|
|
| Researchers examined immune cell subsets in hospitalized and non-hospitalized individuals. In hospitalized patients, many adaptive and innate immune cells were decreased in frequency compared to healthy and convalescent individuals, with the exception of B lymphocytes which increased
[Journal of Clinical Investigation] |
|
|
|
| Scientists report their discovery that the ACE2 receptor protein robustly localized within the motile cilia of airway epithelial cells, which likely represented the initial or early subcellular site of SARS-CoV-2 viral entry during host respiratory transmission.
[Nature Communications] |
|
|
|
| Scientists identified SARS-CoV-2 membrane glycoprotein M as a negative regulator of the innate immune response. They found that the M protein interacted with the central adaptor protein MAVS in the innate immune response pathways.
[Cellular & Molecular Immunology] |
|
|
|
| MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
| | To facilitate pathogenesis studies in vivo, scientists developed an inducible CRISPR interference system that enabled genome-wide fitness testing in one sequencing step
[Cell Host & Microbe] |
|
|
|
| To develop a tuberculosis model that more closely resembled human disease, scientists infected mice with an ultra-low dose of between one to three founding bacteria, reflecting a physiologic inoculum.
[Cell Host & Microbe] |
|
|
|
| Investigators evaluated the origin of rebound virus in 16 antiretroviral therapy (ART)-suppressed, chronically SIV-infected rhesus monkeys following ART discontinuation. They sequenced viral RNA and viral DNA in these animals prior to ART initiation, during ART suppression, and following viral rebound
[Nature Communications] |
|
|
|
| Researchers established an immunocompetent syngeneic pancreatic ductal adenocarcinoma model, and investigated the effect of oncolytic herpes simplex virus-1 on the composition of tumor microenvironment immune cells.
[Molecular Therapy] |
|
|
|
| Adoptive transfer of CD4+ T cells from mice that had experienced bacterial infection into influenza A virus-infected mice revealed that memory protection against bacteria was weakened in the latter.
[iScience] |
|
|
|
| Investigators assessed the efficiency of dengue virus infection using the novel immortalized human myeloid cell lines iPS-ML and iPS-dendritic cell.
[Heliyon] |
|
|
|
|
| Scientists explore how self-amplifying RNAs are emerging as important vaccine candidates for infectious diseases, the advantages of synthetic manufacturing approaches, and their potential for preventing and treating chronic infections.
[Gene Therapy] |
|
|
|
|
| Histogen, Inc. announced entering into a Collaborative Development and Commercialization Agreement with Amerimmune LLC to jointly develop emricasan, an orally active caspase inhibitor, for the treatment of COVID-19.
[Histogen, Inc.] |
|
|
|
| CEPI, the Coalition for Epidemic Preparedness Innovations, announced that it will fund the development of the protein-based S-Trimer COVID-19 vaccine candidate by Sichuan Clover Biopharmaceuticals, Inc. through a global pivotal Phase II/III efficacy clinical trial and to licensure in China and globally, if the vaccine is proven to be safe and effective.
[CEPI] |
|
|
|
| Humanigen, Inc. announced the execution of its first licensing transaction in the Asia-Pacific Region with Telcon RF Pharmaceutical, Inc. and KPM Tech Co., Ltd for development and commercialization rights to lenzilumab for COVID-19 for South Korea and the Philippines.
[Humanigen, Inc.] |
|
|
|
|
| April 11 – April 13, 2021
San Diego, California, United States |
|
|
|
|
|
| | MRC Laboratory of Molecular Biology – Cambridge, England, United Kingdom |
|
|
|
| | Queen’s University – Kingston, Ontario, Canada |
|
|
|
| | Lerner Research Institute – Cleveland, Ohio, United States |
|
|
|
| | Swiss Federal Institute of Technology in Lausanne – Lausanne, Vaud, Switzerland |
|
|
|
| | Fred Hutchinson Cancer Research Center – Seattle, Washington, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
